Literature DB >> 3733150

Enhancement of immunogenicity of tumour virus antigen by liposomes: the effect of lipid composition.

O Bakouche, D Gerlier.   

Abstract

The secondary humoral response evoked in W/Fu rats by the weakly immunogenic soluble Gross cell surface antigen (GCSAa) extracted from the syngeneic (C58NT)D lymphoma can be enhanced when GCSAa is presented in liposomes, and this requires the antigen to be strongly associated with the phospholipid bilayers. In order to investigate further the role of the phospholipid microenvironment in the membrane presentation of this antigen, the relationship between the phospholipid composition and the immunogenic potency of GCSAa liposomes was explored. For a given neutral phospholipid component, optimal immunogenicity was obtained when 20% cholesterol was present and when a negatively charged phospholipid was included as a minor component. When phosphatidylcholines (PC) were used as the major neutral component, the immunogenicity of GCSAa liposomes from optimal for distearoyl PC (DSPC) decreased when decreasing the PC acyl chain length down to the background level for dilauroyl PC (DLPC). Similarly, the use of PC with acyl chain of increasing unsaturation was followed by a decline in the immunogenicity of the GCSAa liposomes up to the background level for dilinoleoyl PC (DLiPC). Replacing PC headgroups by phosphatidylethanolamine (PE) headgroups abolished the enhancing effect of the liposome presentation on GCSAa immunogenicity. Three groups of phospholipids unable to promote the expression of the GCSAa immunogenicity could be distinguished: the DLPC, DLiPC group, unable to prime the animals but, contrary to the soluble antigen, able to boost the animal after an appropriate priming with GCSAa-DSPC-liposomes, the dimyristoyl PE group, unable to prime or to boost and non-toxic in vitro for the macrophages, and the dipalmitoyl PE group, acutely toxic for macrophages.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733150      PMCID: PMC1453458     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  26 in total

1.  The inability of macrophages to digest liposomes containing a high proportion of cholesterol.

Authors:  S M Johnson
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

2.  Hepatitis B surface antigen-containing liposomes enhance humoral and cell-mediated immunity to the antigen.

Authors:  E K Manesis; C H Cameron; G Gregoriadis
Journal:  FEBS Lett       Date:  1979-06-01       Impact factor: 4.124

3.  Liposomes as immunological adjuvants.

Authors:  A G Allison; G Gregoriadis
Journal:  Nature       Date:  1974-11-15       Impact factor: 49.962

4.  Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells.

Authors:  G Gregoriadis; C Davis
Journal:  Biochem Biophys Res Commun       Date:  1979-08-28       Impact factor: 3.575

5.  Effect of liposomal model membrane composition on immunogenicity.

Authors:  G F Dancey; T Yasuda; S C Kinsky
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

6.  Immunogenic properties of liposomal model membranes in mice.

Authors:  T Yasuda; G F Dancey; S C Kinsky
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

7.  Characterization of immunogenic properties of haptenated liposomal model membranes in mice. I. Thymus independence of the antigen.

Authors:  A J van Houte; H Snippe; J M Willers
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

8.  Identification of the Gross cell surface antigen associated with murine leukemia virus-infected cells.

Authors:  J Ledbetter; R C Nowinski
Journal:  J Virol       Date:  1977-08       Impact factor: 5.103

9.  Characterization of molecular species carrying gross cell surface antigen.

Authors:  H W Snyder; E Stockert; E Fleissner
Journal:  J Virol       Date:  1977-08       Impact factor: 5.103

10.  Immunogenicity of liposomal model membranes in mice: dependence on phospholipid composition.

Authors:  T Yasuda; G F Dancey; S C Kinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1977-03       Impact factor: 11.205

View more
  10 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Synthetic macrophages: antigen presentation by liposomes bearing class II major histocompatibility complex (MHC) and membrane interleukin-1 (IL-1).

Authors:  O Bakouche; L B Lachman
Journal:  J Clin Immunol       Date:  1989-09       Impact factor: 8.317

3.  Immunogenicity of liposomes and iscoms containing the major outer membrane protein of Neisseria gonorrhoeae: influence of protein content and liposomal bilayer composition.

Authors:  G F Kersten; A M van de Put; T Teerlink; E C Beuvery; D J Crommelin
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

4.  Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides.

Authors:  Melissa C Hanson; Wuhbet Abraham; Monica P Crespo; Stephanie H Chen; Haipeng Liu; Greg Lee Szeto; Mikyung Kim; Ellis L Reinherz; Darrell J Irvine
Journal:  Vaccine       Date:  2015-01-02       Impact factor: 3.641

5.  Immunomodulation by liposome entrapped allergen.

Authors:  N Arora; S V Gangal
Journal:  Mol Cell Biochem       Date:  1990-09-21       Impact factor: 3.396

6.  In vitro cellular immune response to measles viral glycoproteins: role of the antigen vector.

Authors:  O Bakouche; B Mougin; D Gerlier
Journal:  Immunology       Date:  1987-12       Impact factor: 7.397

7.  Antigen presentation by liposomes bearing class II MHC and membrane IL-1.

Authors:  O Bakouche; L B Lachman
Journal:  Yale J Biol Med       Date:  1990 Mar-Apr

Review 8.  Induction of Plasmodium-Specific Immune Responses Using Liposome-Based Vaccines.

Authors:  Aloysious Ssemaganda; Ashwini Kumar Giddam; Mehfuz Zaman; Mariusz Skwarczynski; Istvan Toth; Danielle I Stanisic; Michael F Good
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 9.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization.

Authors:  Ning Wang; Minnan Chen; Ting Wang
Journal:  J Control Release       Date:  2019-05-03       Impact factor: 9.776

10.  Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators.

Authors:  Christophe Barnier-Quer; Abdelrahman Elsharkawy; Stefan Romeijn; Alexander Kros; Wim Jiskoot
Journal:  Pharmaceutics       Date:  2013-07-25       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.